Some images has been designed using resources from Unsplash & Pixabay & Pexels & Freepik and some icons from Flaticon
跳到主要內容
:::
:::

江晨恩醫師

 

 

 

江晨恩醫師   Chern-En Chiang, M.D., Ph.D.
學位:

   陽明大學臨床醫學研究所博士
   陽明大學醫學士

.................................................................................................................................................
現職:    臺北榮民總醫院新藥臨床試驗中心主任
   臺北榮民總醫院內科部心臟內科主治醫師
...............................................................................................................................................................................................
教 職:

   國立陽明交通大學內科學科教授

...............................................................................................................................................................................................

經 歷:

  • 臺北榮民總醫院心臟科總醫師 
  • 臺北榮民總醫院內科部住院醫師
  • 美國范得堡醫學院臨床藥理博士後研
  • 中華民國心臟學會副理事長
  • 中華民國心臟學會/臺灣高血壓學會2010, 2015, 2017高血壓治療指南主席
  • 中華民國心臟學會/臺灣高血壓學會2022高血壓治療指南共同主席
  • 臺灣心律學會/臺灣心臟學會2016心房顫動治療指南主席 
  • 亞太心律學會(APHRS) 2017心房顫動中風預防指南主席 
  • 中華民國心臟學會/中華民國糖尿病學會2018糖尿病合併心血管病治療指南主席 
  • 中華民國心臟學會2020糖尿病合併心血管病治療指南主席
...............................................................................................................................................................................................
專長學科:
  • 成人心臟內科
  • 臨床試驗 Clinical Trial
  • 電氣藥理 Electropharmacology
  • 高血壓 Hypertension
  • 脂類學 Lipidiology
  • 心臟衰竭 Heart Failure
  • 著  作:   國際醫學期刊 329篇。

    (New England Journal of Medicine, JAMA, Lancet Diabetes Endocrinology, Annals of Internal Medicine, European Heart Journal, Circulation, JACC, etc.)

    Editorial Board: Circulation, JACC-Heart Failure, Current Hypertension Report, Journal of Chinese Medical Association, Journal of Arrhythmia, International Journal of Arrhythmia                                                                                    
  • 國際臨床試驗經驗:  >80個
  • 40個為臺灣總主持人 (AMISH, AVE/7688 [II], CRESCENDO, YM150 [II], COSIMA 2, LCZ696 [II], RECOVER 2, CEPHEUS, ENGAGE-TIMI 48, SIGNIFY, REALISEAF, T-EMERGE, SAVOR-TIMI 53, LAVENDER, ARTEMIS, ELIXA, Dronedarone PK, TAK-875 304, TAK-875 306, TAK-875 307, ACCELERATE, DECLARE-TIMI 58, ODYSSEY CVOT, CEPHEUS-5S, THEMIS, EINSTEIN CHOICE, GARFIELD-VTE, STRENGTH, ODYSSEY-KT, HARMONY, VICTORIA,ENTRUST, DAPA-HF, BET-MACE, SCORED, DELIVER, SURPASS-CVOT, FINEARTS-HF, Lp(a)HORIZON, MIRACLE)
  • 17個為全球Steering Committee Member (AMISH, COSIMA 2, CEPHEUS, SIGNIFY, REALISEAF, SAVOR-TIMI53, ACCELERATE, DECLARE-TIMI58, ODYSSEY, THEMIS, STRENGTH, ROSTAFUROXIN HT trial, VICTORIA,DAPA-HF, SCORED, DELIVER, FINEARTS-HF)
  • 國內外應邀演講: 2006-2021年3331場
  • 陽明大學教學績優獎: 2002-2021年
...............................................................................................................................................................................................

專科學會:

  • 中華民國內科醫學會
  • 中華民國心臟學會
  • 中華民國血脂學會
  • 美國心電生理學會
...............................................................................................................................................................................................
通訊處:        臺北市石牌路二段201號科技大樓新藥臨床試驗中心
...............................................................................................................................................................................................
E-mail:

        cechiang@vghtpe.gov.tw

...............................................................................................................................................................................................

 

重要著作:

  1. McMurray JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Anand IS, Bělohlávek J, Böhm M, Chiang CE, Chopra VK, de Boer RA, Desai AS, Diez M, Drozdz J, Dukát A, Ge J, Howlett JG, Katova T, Kitakaze M, Ljungman CEA, Merkely B, Nicolau JC, O'Meara E, Petrie MC, Vinh PN, Schou M, Tereshchenko S, Verma S, Held C, DeMets DL, Docherty KF, Jhund PS, Bengtsson O, Sjöstrand M, Langkilde AM; DAPA-HF Trial Committees and Investigators. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019 ;381(21):1995-2008.
  2. Wang KL, Lopes RD, Patel MR, Büller HR, Tan DS, Chiang CE, Giugliano RP. Efficacy and safety of reduced-dose non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: a meta-analysis of randomized controlled trials. Eur Heart J. 2019 May 14;40(19):1492-1500.
  3. Petrie MC, Verma S, Docherty KF, Inzucchi SE, Anand I, Belohlávek J, Böhm M, Chiang CE, Chopra VK, de Boer RA, Desai AS, Diez M, Drozdz J, Dukát A, Ge J, Howlett J, Katova T, Kitakaze M, Ljungman CEA, Merkely B, Nicolau JC, O'Meara E, Vinh PN, Schou M, Tereshchenko S, Køber L, Kosiborod MN, Langkilde AM, Martinez FA, Ponikowski P, Sabatine MS, Sjöstrand M, Solomon SD, Johanson P, Greasley PJ, Boulton D, Bengtsson O, Jhund PS, McMurray JJV. Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes. JAMA. 2020 ;323(14):1353-1368.
  4. Martinez FA, Serenelli M, Nicolau JC, Petrie MC, Chiang CE, Tereshchenko S, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Ponikowski P, Sabatine MS, DeMets DL, Dutkiewicz-Piasecka M, Bengtsson O, Sjöstrand M, Langkilde AM, Jhund PS, McMurray JJV. Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age: Insights From DAPA-HF. Circulation. 2020 Jan 14;141(2):100-111.
  5. Sinnaeve PR, Schwartz GG, Wojdyla DM, Alings M, Bhatt DL, Bittner VA, Chiang CE, Correa Flores RM, Diaz R, Dorobantu M, Goodman SG, Jukema JW, Kim YU, Pordy R, Roe MT, Sy RG, Szarek M, White HD, Zeiher AM, Steg PG; ODYSSEY OUTCOMES Investigators. Effect of alirocumab on cardiovascular outcomes after acute coronary syndromes according to age: an ODYSSEY OUTCOMES trial analysis. Eur Heart J. 2020 ;41(24):2248-2258.
  6. Serenelli M, Böhm M, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Solomon SD, DeMets DL, Bengtsson O, Sjöstrand M, Langkilde AM, Anand IS, Chiang CE, Chopra VK, de Boer RA, Diez M, Dukát A, Ge J, Howlett JG, Katova T, Kitakaze M, Ljungman CEA, Verma S, Docherty KF, Jhund PS, McMurray JJV. Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF). Eur Heart J. 2020 ;41(36):3402-3418.
  7. Kohsaka S, Lam CSP, Kim DJ, Cavender MA, Norhammar A, Jørgensen ME, Birkeland KI, Holl RW, Franch-Nadal J, Tangri N, Shaw JE, Ilomäki J, Karasik A, Goh SY, Chiang CE, Thuresson M, Chen H, Wittbrodt E, Bodegård J, Surmont F, Fenici P, Kosiborod M; CVD-REAL 2 Investigators and Study Group. Risk of cardiovascular events and death associated with initiation of SGLT2 inhibitors compared with DPP-4 inhibitors: an analysis from the CVD-REAL 2 multinational cohort study. Lancet Diabetes Endocrinol.2020 ;8(7):606-615.
  8. Jhund PS, Ponikowski P, Docherty KF, Gasparyan SB, Böhm M, Chiang CE, Desai AS, Howlett J, Kitakaze M, Petrie MC, Verma S, Bengtsson O, Langkilde AM, Sjöstrand M, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, Sabatine MS, Solomon SD, McMurray JJV. Dapagliflozin and Recurrent Heart Failure Hospitalizations in Heart Failure With Reduced Ejection Fraction: An Analysis of DAPA-HF. Circulation. 2021 ;143(20):1962-1972.
  9. White HD, Schwartz GG, Szarek M, Bhatt DL, Bittner VA, Chiang CE, Diaz R, Goodman SG, Jukema JW, Loy M, Pagidipati N, Pordy R, Ristić AD, Zeiher AM, Wojdyla DM, Steg PG; ODYSSEY OUTCOMES Investigators. Alirocumab after acute coronary syndrome in patients with a history of heart failure. Eur Heart J. 2022 ;43(16):1554-1565.
  10. Solomon SD, Vaduganathan M, Claggett BL, de Boer RA, DeMets D, Hernandez AF, Inzucchi SE, Kosiborod MN, Lam CSP, Martinez F, Shah SJ, Belohlavek J, Chiang CE, Willem Borleffs CJ, Comin-Colet J, Dobreanu D, Drozdz J, Fang JC, Alcocer Gamba MA, Al Habeeb W, Han Y, Cabrera Honorio JW, Janssens SP, Katova T, Kitakaze M, Merkely B, O'Meara E, Kerr Saraiva JF, Tereschenko SN, Thierer J, Vardeny O, Verma S, Vinh PN, Wilderäng U, Zaozerska N, Lindholm D, Petersson M, McMurray JJV. Baseline Characteristics of Patients With HF With Mildly Reduced and Preserved Ejection Fraction: DELIVER Trial. JACC Heart Fail.2022 ;10(3):184-197.
  11. Butt JH, Dewan P, Merkely B, Belohlávek J, Drożdż J, Kitakaze M, Inzucchi SE, Kosiborod MN, Martinez FA, Tereshchenko S, Ponikowski P, Bengtsson O, Lindholm D, Langkilde AM, Schou M, Sjöstrand M, Solomon SD, Sabatine MS, Chiang CE, Docherty KF, Jhund PS, Køber L, McMurray JJV. Efficacy and Safety of Dapagliflozin According to Frailty in Heart Failure With Reduced Ejection Fraction : A Post Hoc Analysis of the DAPA-HF Trial. Ann Intern Med. 2022 ;175(6):820-830.

限於篇幅,以上謹為代表著作 

最後更新:

回到最上